EUVIMEDEUVIMED entdecken
Crossref

Investigation through naphtho[2,3‐a]pyrene on mutated EGFR mediated autophagy in NSCLC : Cellular model system unleashing therapeutic potential

Nikhil Samarth, Pooja Gulhane, Shailza Singh iD

IUBMB Life · 2024

DOI: 10.1002/iub.2914 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IUBMB Life, 2024. Verfasst von Nikhil Samarth und 2 weiteren Autor:innen. Beteiligte Einrichtung: Systems Medicine Laboratory, Biotechnology Research and Innovation Council-National Centre for Cell Science (BRIC-NCCS), NCCS Complex, Pune, India. Hauptthemen laut MEDLINE: ErbB Receptors, Autophagy, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutant epidermal growth factor receptor (EGFR) signaling has emerged as a key cause of carcinogenesis and therapy resistance in non‐small cell lung cancer (NSCLC), which continues to pose a serious threat to world health. In this study, we aimed to elucidate the complex molecular pathways of EGFR‐mediated autophagy signaling in NSCLC. We identified naphtho[2,3‐a]pyrene, an anthraquinolone derivative, to be a promising investigational drug that targets EGFR‐mediated autophagy using a cellular model system. By utilizing systems biology, we developed a computational model that explained the signaling of EGFR‐mediated autophagy and identified critical crosstalk sites that could be inhibited therapeutically. As a lead compound, naphtho[2,3‐a]pyrene was confirmed by molecular docking experiments. It was found to be cytotoxic to NSCLC cells, impact migration, induce apoptosis, and arrest cell cycle, both on its own and when combined with standard drugs. The anticancer efficacy of naphtho[2,3‐a]pyrene was validated in vivo on CDX nude mice. It showed synergistic activity against NSCLC when coupled with gefitinib, chloroquine, and radiation. Altogether, our study highlights naphtho[2,3‐a]pyrene's therapeutic promise in NSCLC by focusing on EGFR‐mediated autophagy and providing a new strategy to fight drug resistance and tumor survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsAutophagyCarcinoma, Non-Small-Cell LungLung NeoplasmsXenograft Model Antitumor AssaysMice, NudeApoptosisHumansAnimalsMiceMutationCell ProliferationMolecular Docking SimulationSignal TransductionCell Line, TumorAntineoplastic AgentsGefitinibCell Movement

Stichwörter der Autor:innen

EGFRNSCLCanthraquinolone derivativeautophagysystems biology

Substanzen

ErbB ReceptorsEGFR protein, humanAntineoplastic AgentsGefitinib

Autor:innen und Institutionen

  • Systems Medicine Laboratory, Biotechnology Research and Innovation Council-National Centre for Cell Science (BRIC-NCCS), NCCS Complex, Pune, India.

ORCID-Profile: Shailza Singh

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India

Zitieren

APA

Samarth, N., Gulhane, P., & Singh, S. (2024). Investigation through naphtho[2,3‐a]pyrene on mutated EGFR mediated autophagy in NSCLC : Cellular model system unleashing therapeutic potential. IUBMB Life. https://doi.org/10.1002/iub.2914

Vancouver

Samarth N, Gulhane P, Singh S. Investigation through naphtho[2,3‐a]pyrene on mutated EGFR mediated autophagy in NSCLC : Cellular model system unleashing therapeutic potential. IUBMB Life. 2024. doi:10.1002/iub.2914

BibTeX
@article{Samarth2024,
  author = {Samarth, Nikhil and Gulhane, Pooja and Singh, Shailza},
  title = {Investigation through naphtho[2,3‐a]pyrene on mutated EGFR mediated autophagy in NSCLC : Cellular model system unleashing therapeutic potential},
  journal = {IUBMB Life},
  year = {2024},
  doi = {10.1002/iub.2914}
}
Kostenlos starten →